CELLUSION
Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
CELLUSION
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2015-01-01
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.cellusion.jp
Total Employee:
1+
Status:
Active
Contact:
81.3.5843.1785
Total Funding:
1.57 B JPY
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Nginx Google Apps For Business Cloudflare JS CDN JS
Similar Organizations
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Gemseki
Gemseki investment in Venture Round - Cellusion
Toho Holdings
Toho Holdings investment in Venture Round - Cellusion
UTEC - The University of Tokyo Edge Capital Partners
UTEC - The University of Tokyo Edge Capital Partners investment in Venture Round - Cellusion
DBJ Capital
DBJ Capital investment in Venture Round - Cellusion
Toyo Seikan Group Holdings
Toyo Seikan Group Holdings investment in Venture Round - Cellusion
Keio Innovation Initiative
Keio Innovation Initiative investment in Venture Round - Cellusion
SMBC Venture Capital
SMBC Venture Capital investment in Venture Round - Cellusion
ITIC: Industrial Technology Investment Corporation
ITIC: Industrial Technology Investment Corporation investment in Venture Round - Cellusion
DBJ Capital
DBJ Capital investment in Series A - Cellusion
SMBC Venture Capital
SMBC Venture Capital investment in Series A - Cellusion
Official Site Inspections
http://www.cellusion.jp Semrush global rank: 6.13 M Semrush visits lastest month: 1.32 K
- Host name: www1088.onamae.ne.jp
- IP address: 160.251.148.186
- Location: Tokyo Japan
- Latitude: 35.6882
- Longitude: 139.7532
- Timezone: Asia/Tokyo
- Postal: 102-0082
More informations about "Cellusion"
CELLUSION โ Regenerate human potential.
Cellusion participated in โBIO Asia-Taiwan 2024โ and CFO Takuya Kaneko made a pitch at the Investment Summit. 2024. 08. 01. BIO Asia-Taiwan 2024, jointly organized by the โฆSee details»
Cellusion Inc. - J-Startup
Cellusion aim to solve unmet medical needs based on "patient-centricity" by creating innovative regenerative medicine using iPS cells from Japan. Currently, corneal transplantation requires โฆSee details»
Cellusion Inc. - j-startup.go.jp
Cellusion aim to solve unmet medical needs based on "patient-centricity" by creating innovative regenerative medicine using iPS cells from Japan. Currently, corneal transplantation requires โฆSee details»
Cellusion - Crunchbase Company Profile & Funding
Organization. Cellusion . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email [email protected]; โฆSee details»
Member Introductions | CELLUSION โ Regenerate human potential.
Medical Director, Japanese Organization for Medical Device Development 2018 Manager, Boston Scientific Corporation Japan 2019 Principal, The University of Tokyo Edge Capital Partners ( โฆSee details»
Cellusion Inc. - BIO International Convention | BIO
Jun 6, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Cellusion is โฆSee details»
Top Interview | CELLUSION โ Regenerate human โฆ
This method is highly robust, suitable for quality control, and eliminates the challenges in technology transfer from our laboratory to a Contract Development and Manufacturing Organization (CDMO). It was around 2017 when we were โฆSee details»
Cellusion Company Profile 2024: Valuation, Funding & Investors
Cellusion General Information Description. Provider of corneal endothelial regenerative medicine intended to improve eye vision. The company's medicines use corneal endothelial cell โฆSee details»
Message by Cellusion Inc. - P.S. i LOVE YOU PROJECT
About the organization Cellusion is a regenerative medicine start-up company out of Keio University School of medicine. Its focus is to research, develop, manufacture, and sell โฆSee details»
CELLUSION, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for CELLUSION, INC. of CHUO-KU, TOKYO. Get the latest business insights from Dun & Bradstreet. โฆSee details»
Cellusion and Minaris Regenerative Medicine, a โฆ
Oct 12, 2022 Cellusion is striving to solve this problem, and by doing so support the UNโs Sustainable Development Goals 3 to ensure healthy lives and promote well-being for all ages. Cellusion has announced that patient recruitment โฆSee details»
History | CELLUSION โ Regenerate human potential.
Shin Hatou, one of the founderโs of Cellusion, began research on corneal endothelium regenerative medicine July 2012 Core technology patent filed to create corneal endothelial โฆSee details»
Cellusion Inc.๏ฝๆ่ณๅ ไผๆฅญ๏ฝUTEC-The University of Tokyo Edge โฆ
Cellusion Inc. is a regenerative medicine startup developing a novel cell therapy product for bullous keratopathy, applied about half of corneal transplantation cases. The company is โฆSee details»
Cellusion and Celregen, a member of Fosun Pharma, Enter into
Sep 12, 2022 Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., โCellusionโ), a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem โฆSee details»
Cellusion Inc. - Tokyo, Japan - bionity.com
Cellusion is a regenerative medicine startup born from the Department of Ophthalmology, Keio University School of Medicine in 2015. Cellusion aims to contribute to the improvement of โฆSee details»
Cellsion wins a prize in the Japan Semi-Final - CELLUSION
Aug 28, 2023 Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., โCellusionโ), a deep tech start-up developing iPS cell-derived corneal endothelial cell substitute for the treatment of bullous โฆSee details»
Cellusion - Overview, News & Similar companies | ZoomInfo.com
Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001 TOKYO--(BUSINESS WIRE)--Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., โCellusionโ), a deep tech start-up developing a โฆSee details»
NEWS | CELLUSION โ Regenerate human potential.
Cellusion will exhibit at HVC KYOTO (Healthcare Venture Conference KYOTO) 2024 Demo Day (Day2), an innovation platform organized by Kyoto Research Park Corp. (KRP) and Japan โฆSee details»
Cellusion Inc. | Insights
Mar 22, 2022 Cellusion Inc. https://cellusion.jp/en/ Industry. Biotechnology. Gene Therapy, Cell Therapy; Pharmaceuticals; See more in Biomedtracker. Latest on Cellusion Inc. Already A โฆSee details»
Cellusion raises 2.83 Billion Yen (21 Million USD) in Series C Round
Jun 7, 2023 Cellusion is promoting the development of CLS001 as a therapeutic regenerative medicine product for bullous keratopathy, which accounts for more than half of the corneal โฆSee details»